Latest Belimumab Stories

Although Physicians are Pleased to Have An Additional Treatment Option for SLE, They Wish Benlysta Had a Broader Indication, According to a New Report from BioTrends Research Group EXTON, Pa., April 25, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the top five unmet needs for new SLE therapies are long-term safety, reduction in disease activity/flares, sustained efficacy,...

BURLINGAME, Calif., April 9, 2013 /PRNewswire/ -- Igenica, Inc., an innovative biopharmaceutical company focused on the discovery and development of first-in-class antibody-based therapeutics for the treatment of cancer, today announced the appointment of Thi-Sau Migone, Ph.D., to the role of Chief Scientific Officer. Dr. Migone brings wide-ranging experience in the discovery and development of novel therapeutic antibodies. Dr. Migone joins Igenica from Human Genome Sciences,...

TALLAHASSEE, Fla., April 3, 2013 /PRNewswire-USNewswire/ -- The Lupus Foundation of Florida applauds the Health Policy committee of the Florida Senate for the passage of Senate Bill 732 out of committee. The legislation will allow biologic medicines to be automatically substituted with interchangeable biosimilar medicines by pharmacists. It would also ensure doctors are made aware of product substitution and ensure records of biosimilar substitution are kept for a reasonable amount...

LONDON, February 12, 2013 /PRNewswire/ -- Any drug company's stock price hinges on the performance of its drugs. One of the very first steps involved in marketing a drug is getting the approval of FDA. Dynavax Technologies Corporation (NASDAQ: DVAX) is one such company that pointed out that the point recently. The stock plummeted when its drug candidate received poor reviews. However, the same Hepatitis B drug is now waiting for the final approval and the FDA's decision will...

Lawrence LeBlond for redOrbit.com - Your Universe Online British pharmaceutical giant GlaxoSmithKline (GSK) has acquired US-based Human Genome Sciences (HGS) after tough negotiations saw it raise offers from an initial $2.6 billion in April, putting the final value of the deal at $3.6 billion or $14.25 per share. By securing HGS, GSK is gaining full control of the drug Benlysta, the first drug in more than 50 years to be approved by the Food and Drug Administration (FDA) for the...

NEW YORK, Feb. 15, 2012 /PRNewswire/ -- The Lupus Research Institute (LRI) today awards 12 "Novel Research Grants" to jumpstart discovery in lupus by supporting original, highly promising ideas from some of the country's most creative scientists. Studies will look at why lupus turns the body's immune system against itself and pioneer strategies for new treatment development. The new awards represent diverse disciplines, from inflammation and medical imaging to evolutionary biology...

WASHINGTON, March 24, 2011 /PRNewswire/ -- Almost 3,000 walkers will celebrate the first drug developed for lupus in more than 50 years during the milestone 5th Annual Walk for Lupus Now! D.C. on Sat., April 16. Approved by the FDA on March 9, BENLYSTA by Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) represents relief for the unrelenting pain faced by many lupus patients whose disease still lacks a cure. American Idol-ready Devin Kowl (http://www.devinkowl.com/), a 15-year-old...

The long path to Benlysta emphasizes importance of basic researchScientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues."I am deeply gratified that our scientific findings have proven so...

WALTHAM, Mass., Aug. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven primarily by the launch and uptake of Human Genome Sciences/GlaxoSmithKline's Benlysta, the systemic lupus erythematosus (SLE) drug market will quadruple from about $400 million in 2009 to more than $1.6 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor...

WALTHAM, Mass., Feb. 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, following its expected regulatory approval in 2011 in the United States and Europe, Human Genome Sciences/GlaxoSmithKline's Benlysta will garner sales of more than $500 million in 2018 in the systemic lupus erythematosus drug market. If approved, Benlysta will be the first agent to launch for systemic lupus erythematosus in...